Form 4: Curis Inc. Director Hohneker Receives Stock Option Grant Following Shareholder Approval

Director John Hohneker receives a stock option grant for 14,400 shares of Curis Inc. following shareholder approval of Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan.

Summary

• John Hohneker, a director of Curis Inc., was granted a non-qualified stock option for 14,400 shares on May 20, 2025.
• The grant was contingent upon shareholder approval of Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan, which increased the number of shares authorized for issuance.
• Shareholder approval was obtained on May 20, 2025, at the company's annual meeting.
• The option has an exercise price of $3.13 per share and vests 100% on January 28, 2026.
• The option expires on January 27, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a routine corporate action, and the shareholder approval indicates confidence in the company's direction. There are no red flags or negative indicators in the filing.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• Shareholder approval of the amendment to the stock incentive plan indicates support for incentivizing company leadership.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the option.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation. The size and terms of the grant are typical for a director-level position.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their directors and align their interests with shareholders.
• The vesting schedule of 100% after one year is fairly standard, as it encourages long-term commitment to the company's success.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the director to contribute to the company's success.
• The grant has a minimal immediate impact on employees, customers, suppliers, and creditors.

Key Dates

Keywords

stock option, Curis Inc, director, shareholder approval, incentive plan, Form 4, Hohneker